| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
Oct 09, 2026 | BUY |
Buy
+82.5% avg upside
43 analysts
|
$31.00
58.27% Upside
|
· | · |
|
BNTX
BioNTech SE
|
Oct 09, 2026 | BUY |
Strong Buy
+43.7% avg upside
28 analysts
|
$114.00
23.89% Upside
|
+0.0% | · |
|
RYTM
Rhythm Pharmaceuticals
|
Oct 09, 2026 | BUY |
Strong Buy
+37.7% avg upside
22 analysts
|
$150.00
67.27% Upside
|
· | · |
|
ASND
Ascendis Pharma
|
Oct 09, 2026 | BUY |
Strong Buy
+26.0% avg upside
27 analysts
|
$304.00
36.61% Upside
|
· | · |
|
RARE
Ultragenyx Pharmaceutical
|
Oct 09, 2026 | HOLD |
Strong Buy
+225.8% avg upside
36 analysts
|
$20.00
30.83% Upside
|
· | · |
|
PTCT
PTC Therapeutics
|
Oct 09, 2026 | BUY |
Buy
+28.7% avg upside
29 analysts
|
$96.00
53.53% Upside
|
· | · |
|
SRPT
Sarepta Therapeutics
|
Oct 09, 2026 | SELL |
Buy
+234.5% avg upside
50 analysts
|
$18.00
1.11% Downside
|
· | · |
|
NBIX
Neurocrine
|
Oct 09, 2026 | BUY |
Strong Buy
+32.2% avg upside
37 analysts
|
$214.00
51.59% Upside
|
+0.0% | · |
|
INCY
Incyte
|
Oct 09, 2026 | BUY |
Buy
-2.5% avg upside
48 analysts
|
$140.00
24.17% Upside
|
· | · |
|
BCRX
BioCryst
|
Oct 09, 2026 | BUY |
Strong Buy
+116.0% avg upside
24 analysts
|
$15.00
81.03% Upside
|
· | · |
|
ALNY
Alnylam Pharma
|
Oct 09, 2026 | BUY |
Strong Buy
+39.7% avg upside
51 analysts
|
$336.00
49.74% Upside
|
+0.0% | · |
|
ARGX
Argenx Se
|
Oct 08, 2026 | BUY |
Strong Buy
-0.2% avg upside
48 analysts
|
— | -0.9% | · |
|
DFTX
Definium Therapeutics
|
Oct 07, 2026 | BUY |
Strong Buy
+50.4% avg upside
23 analysts
|
$91.00
166.19% Upside
|
· | · |
|
ARVN
Arvinas Holding Company
|
Oct 07, 2026 | HOLD |
Strong Buy
+269.9% avg upside
28 analysts
|
$16.00
113.08% Upside
|
· | · |
|
REGN
Regeneron
|
Oct 01, 2026 | BUY |
Strong Buy
+7.3% avg upside
59 analysts
|
$891.00
20.45% Upside
|
+0.7% | · |
|
IMMX
Immix Biopharma
|
Sep 29, 2026 | BUY |
Strong Buy
+133.3% avg upside
9 analysts
|
$30.00
222.93% Upside
|
-7.0% | · |
|
VRTX
Vertex Pharmaceuticals
|
Sep 29, 2026 | BUY |
Strong Buy
-12.9% avg upside
62 analysts
|
— | -4.4% | · |
|
ANNX
Annexon Biosciences
|
Sep 28, 2026 | BUY |
Strong Buy
+253.2% avg upside
14 analysts
|
$8.00
100.04% Upside
|
+4.7% | · |
|
AMGN
Amgen
|
Sep 22, 2026 | SELL |
Buy
-20.3% avg upside
57 analysts
|
$317.00
22.29% Downside
|
+1.8% | · |
|
PBLS
Parabilis Medicines, Inc.
|
Sep 16, 2026 | BUY |
Strong Buy
+49.0% avg upside
6 analysts
|
$45.00
60.13% Upside
|
-24.1% | · |
|
SRRK
Scholar Rock Holding
|
Sep 16, 2026 | BUY |
Strong Buy
+54.8% avg upside
23 analysts
|
$72.00
70.63% Upside
|
-14.0% | · |
|
OCUL
Ocular Therapeutix
|
Sep 15, 2026 | BUY |
Strong Buy
+229.2% avg upside
21 analysts
|
$27.00
259.49% Upside
|
-28.0% | · |
|
KYMR
Kymera Therapeutics
|
Sep 14, 2026 | BUY |
Strong Buy
+1.0% avg upside
37 analysts
|
$144.00
31.68% Upside
|
-4.2% | · |
|
PHVS
Pharvaris
|
Sep 08, 2026 | HOLD |
Strong Buy
+78.8% avg upside
15 analysts
|
$44.00
41.36% Upside
|
-18.9% | · |
|
BLTE
Belite Bio, Inc. ADR
|
Sep 02, 2026 | BUY |
Strong Buy
+31.6% avg upside
11 analysts
|
$200.00
31.19% Upside
|
-0.9% | · |
|
PRTA
Prothena
|
Aug 14, 2026 | SELL |
Buy
+182.9% avg upside
14 analysts
|
— | +7.3% | · |
|
STRO
Sutro Biopharma
|
Aug 14, 2026 | SELL |
Strong Buy
+176.3% avg upside
22 analysts
|
— | +29.4% | · |
|
TSHA
Taysha Gene Therapies
|
Aug 14, 2026 | BUY |
Strong Buy
+217.8% avg upside
22 analysts
|
— | -24.8% | · |
|
ANRO
Alto Neuroscience, Inc.
|
Aug 14, 2026 | BUY |
Strong Buy
+32.6% avg upside
13 analysts
|
— | -26.3% | · |
|
AARD
Aardvark Therapeutics, Inc.
|
Aug 14, 2026 | SELL |
Buy
+309.8% avg upside
12 analysts
|
— | +20.2% | · |
|
BCAX
Bicara Therapeutics Inc.
|
Aug 11, 2026 | BUY |
Strong Buy
+90.6% avg upside
16 analysts
|
$34.00
96.89% Upside
|
-29.1% | · |
|
PEPG
PepGen Inc.
|
Aug 07, 2026 | SELL |
Strong Buy
+313.6% avg upside
9 analysts
|
$2.50
5.13% Upside
|
+20.0% | · |
|
FULC
Fulcrum Therapeutics
|
Aug 07, 2026 | SELL |
Hold
+166.9% avg upside
14 analysts
|
$3.00
20.05% Downside
|
+5.1% | · |
|
DNLI
Denali Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+104.6% avg upside
24 analysts
|
$31.00
65.99% Upside
|
-19.8% | · |
|
GILD
Gilead Sciences
|
Aug 05, 2026 | BUY |
Strong Buy
-19.3% avg upside
66 analysts
|
$162.00
10.16% Upside
|
+10.6% | · |
|
GB:0QW0
arGEN X
|
Jul 02, 2026 | BUY |
Strong Buy
-19.2% avg upside
25 analysts
|
— | · | · |
|
FATE
Fate Therapeutics
|
May 21, 2026 | HOLD |
Buy
+465.7% avg upside
31 analysts
|
$2.20
3.20% Upside
|
+10.5% | · |
|
NMRA
Neumora Therapeutics, Inc.
|
Apr 01, 2025 | SELL |
Buy
+1491.7% avg upside
11 analysts
|
$1.00
108.36% Upside
|
+45.2% | · |
|
FDMT
4D Molecular Therapeutics
|
Sep 19, 2024 | BUY |
Strong Buy
+166.2% avg upside
16 analysts
|
$79.00
521.99% Upside
|
+12.7% | · |
|
ADCT
ADC Therapeutics
|
Oct 17, 2023 | SELL |
Strong Buy
+224.9% avg upside
12 analysts
|
$1.00
37.20% Downside
|
-432.6% | · |
|
OBX
Obsidian Therapeutics
|
Aug 11, 2023 | SELL |
Buy
+32.4% avg upside
11 analysts
|
$0.50
95.92% Downside
|
· | · |
|
PYXS
Pyxis Oncology
|
May 24, 2023 | HOLD |
Strong Buy
+311.6% avg upside
15 analysts
|
$4.00
100.91% Upside
|
-63.2% | · |
|
PRLD
Prelude Therapeutics
|
Mar 27, 2023 | SELL |
Buy
+179.5% avg upside
7 analysts
|
$6.00
54.72% Upside
|
+89.1% | · |
|
PRAX
Praxis Precision Medicines
|
Mar 06, 2023 | HOLD |
Strong Buy
+113.7% avg upside
24 analysts
|
$22.50
91.41% Downside
|
· | · |
|
SQZB
SQZ Biotechnologies
|
Dec 01, 2022 | SELL |
Buy
+102677.8% avg upside
7 analysts
|
$20.00
83233.34% Upside
|
· | · |
|
SRZN
Surrozen
|
Nov 16, 2022 | SELL |
Buy
+36.8% avg upside
8 analysts
|
$1.00
96.42% Downside
|
+51.5% | · |
|
KALA
KALA BIO
|
Jul 21, 2021 | BUY |
Strong Buy
+66599.7% avg upside
9 analysts
|
$8.00
2597.21% Upside
|
· | · |
|
MRNA
Moderna
|
Jan 25, 2021 | HOLD |
Hold
-47.8% avg upside
38 analysts
|
$150.00
23.94% Downside
|
+31.3% | · |
|
QNCX
Quince Therapeutics
|
Jun 03, 2019 | HOLD |
Buy
+452.1% avg upside
18 analysts
|
$28.00
4.66% Downside
|
· | · |
|
ALEC
Alector
|
Mar 04, 2019 | BUY |
Buy
+396.5% avg upside
15 analysts
|
$26.00
1187.16% Upside
|
-22.1% | · |
|
DBVT
DBV Technologies SA - American
|
Dec 20, 2018 | SELL |
Strong Buy
+150.9% avg upside
15 analysts
|
$8.00
16.17% Downside
|
+47.7% | · |
|
PCRX
Pacira Pharmaceuticals
|
Oct 10, 2018 | HOLD |
Buy
+4.8% avg upside
23 analysts
|
$48.00
31.84% Upside
|
+27.2% | · |
|
MCRB
Seres Therapeutics
|
Aug 03, 2018 | SELL |
Buy
+522.1% avg upside
11 analysts
|
$6.00
128.13% Upside
|
· | · |
|
ACET
Adicet Bio
|
Feb 20, 2018 | BUY |
Strong Buy
+353.7% avg upside
14 analysts
|
$23.00
300.71% Upside
|
· | · |
|
SPRO
Spero Therapeutics
|
Nov 27, 2017 | HOLD |
Buy
+1098.1% avg upside
12 analysts
|
$16.00
1303.55% Upside
|
-16.1% | · |
|
RMTI
Rockwell Med
|
Nov 08, 2016 | SELL |
Buy
+69.6% avg upside
11 analysts
|
$5.00
37.72% Downside
|
· | · |
|
CORT
Corcept Therapeutics
|
Jun 02, 2016 | SELL |
Buy
-43.9% avg upside
16 analysts
|
$5.00
95.74% Downside
|
-196.0% | · |
|
INVA
Innoviva
|
Sep 09, 2015 | SELL |
Buy
+39.9% avg upside
13 analysts
|
$13.00
37.66% Downside
|
-29.2% | · |
|
GLNG
Golar LNG
|
Sep 19, 2014 | BUY |
Strong Buy
-7.3% avg upside
22 analysts
|
$110.00
127.22% Upside
|
-67.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.